STEM CELL SCIENCES
Dead / Abandoned — Abandoned — failure to respond (as of 07 Nov 2023)
What this means for you
This application is over — abandoned 13 Sept 2023. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 97392934
- Mark type
- Stylized text
- Filed
- 03 May 2022
- Abandoned
- 13 Sept 2023
- Attorney of record
- Sona Dalal
Goods and services
- Class 005 — Pharmaceuticals: Stem cells for medical purposes; pharmaceuticals derived from stem cells and used for anti-aging, age reversal, and for the treatment of cardiac disease, neurodegenerative disease, musculoskeletal trauma, neurological trauma, type 1 diabetes, liver disease, lung disease, pancreatic disease, psychosis, and psychiatric disorder; Nutraceuticals for use as a dietary supplement; Nutraceuticals for the treatment of or reversal of aging and age-related disease; nutraceuticals for use as a dietary supplement for the intended benefit of reversing the aging process and age-related disease; Nutraceuticals derived from stem cells and for use as a dietary supplement for the intended benefit of reversing the aging process and age-related disease; Nutraceuticals for use as a dietary supplement for the intended benefit of anti-aging, age reversal, treatment of cardiac disease, neurodegenerative disease, musculoskeletal trauma, neurological trauma, type 1 diabetes, liver disease, lung disease, pancreatic disease, psychosis, and psychiatric disorder; Nutraceuticals derived from stem cells for use as a dietary supplement for the intended benefit of anti-aging, age reversal, treatment of cardiac disease, neurodegenerative disease, musculoskeletal trauma, neurological trauma, type 1 diabetes, liver disease, lung disease, pancreatic disease, psychosis, and psychiatric disorder
- Class 044 — Medical, beauty and agricultural services: Stem cell therapy services; medical services relating to the removal, treatment, and processing of stem cells; Medical services to slow or reverse human biological aging processes; anti-aging or longevity medical services; Medical services relating to the treatment of cardiac disease, a neurodegenerative disease, a musculoskeletal trauma, a neurological trauma, type 1 diabetes, liver disease, lung disease, pancreatic disease, psychosis, and psychiatric disorder; medical services, namely, the administration of compositions to humans for the purpose of slowing or reversing human biological aging processes, treating cardiac disease, treating neurodegenerative disease, treating musculoskeletal trauma, treating neurological trauma, treating type 1 diabetes, treating liver disease, treating lung disease, treating pancreatic disease, treating psychosis, and treating psychiatric disorder; medical services, namely, the administration of stem-cell based compositions to humans for the purpose of slowing or reversing human biological aging processes, treating cardiac disease, treating neurodegenerative disease, treating musculoskeletal trauma, treating neurological trauma, treating type 1 diabetes, treating liver disease, treating lung disease, treating pancreatic disease, treating psychosis, and treating psychiatric disorder; medical services, namely, stem-cell based treatments for the purpose of slowing or reversing human biological aging processes, treating cardiac disease, treating neurodegenerative disease, treating musculoskeletal trauma, treating neurological trauma, treating type 1 diabetes, treating liver disease, treating lung disease, treating pancreatic disease, treating psychosis, and treating psychiatric disorder
Owner
- Todd Frank Ovokaitys, Carlsbad, CA, US
Prosecution history
- 08 Nov 2023 — ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
- 07 Nov 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
- 07 Nov 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 08 Jun 2023 — APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
- 08 Jun 2023 — APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
- 12 Mar 2023 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
- 12 Mar 2023 — NON-FINAL ACTION E-MAILED
- 12 Mar 2023 — NON-FINAL ACTION WRITTEN
- 21 Feb 2023 — ASSIGNED TO EXAMINER
- 07 May 2022 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 06 May 2022 — NEW APPLICATION ENTERED